The Food and Drug Administration (FDA) said today it awarded $225 million of contracts to three companies to help the agency’s Center for Biologics Evaluation and Research (CBER) improve its medical review tools. Acumen, Dovel Technologies and IQVIA each received $75 million contracts to “expand and enhance the current CBER capabilities with respect to data sources, infrastructure, methods, and tools and to conduct surveillance and epidemiologic studies that promote CBER’s Office of Biostatistics and Epidemiology’s mission to assure the safety and effectiveness of biologic products.” The awarded contracts have a five-year ordering period.

Read More About
More Topics